Downloaded from https://www.lawinsider.

com/clause/consideration/equity-investment

Equity Investment Sample Clauses

Equity Investment. Facet and Trubion have entered into the Stock Purchase Agreement attached
hereto as Exhibit C, pursuant to which Facet will purchase from Trubion and Trubion will sell to Facet Ten
Million Dollars ($10,000,000.00) of newly issued shares of common stock of Trubion at a purchase price per
share equal to One Hundred Thirty-Five Percent (135%) of the average closing price of a share of common
stock of Trubion over the sixty (60) trading days prior to the Signing Date provided that such purchase price
(including the 35% premium) shall not be greater than $[ * ]/share or lower than $[ * ]/share of common
stock of Trubion. [ See all variations ]
Appears in 4 contracts from 2 different companies: Collaboration and License Agreement (Facet Biotech),
Collaboration and License Agreement (Trubion Pharmaceuticals, Inc.), Collaboration and License
Agreement (Trubion Pharmaceuticals, Inc.)

Equity Investment. Within 14 days of the Effective Date, Alteon shall execute a share purchase
agreement substantially in the form of Exhibit X hereto, for the purchase by Alteon and issuance by OXIS of
Common Shares of OXIS, at a *** to the per share of common stock ***, but in any event not less than $***
per share, and for a total investment sum of $500,000. Such issued shares shall be held by Alteon for not less
than *** from the date of their issuance (it being understood that Alteon may not transfer in any manner such
shares during this *** period, except as may be required by law). During such *** period, OXIS shall use its
commercially reasonable efforts to prepare a registration statement covering such shares (which may be also
included in the context of *** so that upon the expiration of such period, the shares may be sold free or
restrictions. Notwithstanding anything to the contrary, in the event that the equity investment by Alteon
contemplated by this Section 3.2 causes under applicable accounting standards and guidelines a requirement
to prepare, review or otherwise generate consolidated financial statements reflecting the financing results of
Alteon and OXIS, the parties hereto agree to use good faith efforts to restructure the equity investment in a
manner so that such principals of consolidation do not apply (e.g. the issuance of non-voting shares) while
preserving the economic benefit of the investment in OXIS.
Appears in 2 contracts from 2 different companies: Exclusive License Agreement (Oxis International),
Exclusive License Agreement (Synvista Therapeutics, Inc)

Equity Investment. Subject to Ironwood obtaining the necessary consents and approvals by its
board and shareholders, within 10 days of Successful U.S. Phase III, Partner will purchase from Ironwood
capital stock of Ironwood (the "Investment") for an aggregate purchase price of $15,000,000 as described in
this Section. In the event that Successful U.S. Phase III occurs prior to an initial public offering by Ironwood,
the Investment will be made pursuant to a Stock Purchase Agreement (as defined below) pursuant to which
Partner will purchase 681,819 shares of a new series of preferred stock at a per share purchase price equal to
$22.00 per share. In such event, the terms of such purchase will be set forth in a stock purchase agreement in
form and substance (including the associated charter amendments and exhibits, the "Stock Purchase
Agreement") as attached hereto as Exhibit E. In the event that Successful U.S. Phase III occurs following an
initial public offering by Ironwood, the Investment will be a purchase of 681,819 shares (as appropriately
adjusted for any stock dividends, combinations, splits, recapitalizations and the like occurring after the
Effective Date) of Series B Common Stock (as such term is defined in the Tenth Amended and Restated
Certificate of Incorporation of Ironwood Pharmaceuticals, Inc. attached as an exhibit to the Stock Purchase
Agreement), or any security into which all shares of Series B Common Stock have converted or been
exchanged prior to such sale, at a per share purchase price equal to $22.00 per share. In such event, the terms
of such purchase will be on customary terms for a private investment in a publicly-traded company.
Appears in 1 contract License Agreement (Ironwood Pharmaceuticals)

Equity Investment. In the event that Curis has provided P&G notice that it will participate in the
co-development of a Selected Compound or Product under this Agreement, at the time of such notice, Curis
may, at its sole option, request that P&G purchase up to $[**] of Curis common stock on terms and
conditions set forth in a stock purchase agreement in a form to be mutually agreed upon by the parties within
90 days after the Effective Date. P&G may, at its sole option, determine whether or not to purchase Curis
common stock and, within 30 days, shall notify Curis in writing, of its decision. In the event that P&G elects

to purchase Curis common stock, within 30 days, Curis shall notify P&G in writing of the number of shares
of Curis common stock to be purchased by P&G; provided, however, that in no event shall the total number
of shares purchased by P&G represent more than 19.9% of the outstanding shares of common stock of Curis
on the date of purchase. P&G agrees that it will not purchase Curis common stock, other than as provided in
this Section 6.3, absent Curis prior written approval.
Appears in 1 contract Research and License Agreement (Curis, Inc.)

Equity Investment. Subject to Ironwood obtaining the necessary consents and approvals by its
board and shareholders, within 10 days of Successful U.S. Phase III, [**] = Portions of this exhibit have been
omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed
separately with the Commission.
Appears in 1 contract License Agreement (Ironwood Pharmaceuticals)